跳至主要内容
临床试验/NCT05294120
NCT05294120
进行中(未招募)
2 期

A Phase II Trial of Reflectance ConfocaL Microscopy And Optical Coherence Tomography Guided RadIation TherapY: CLARITY

Memorial Sloan Kettering Cancer Center14 个研究点 分布在 1 个国家目标入组 38 人2022年3月3日

概览

阶段
2 期
干预措施
Reflectance ConfocaL Microscopy And Optical Coherence Tomography Guided
疾病 / 适应症
Basal Cell Carcinoma
发起方
Memorial Sloan Kettering Cancer Center
入组人数
38
试验地点
14
主要终点
histologic tumor response rate
状态
进行中(未招募)
最后更新
12天前

概览

简要总结

The purpose of this study is to find out if radiation therapy (RT) guided by the new reflectance confocal microscopy (RCM)/optical coherence tomography (OCT) device is an effective treatment for basal cell carcinoma (BCC). The researchers will also look at the side effects from RT guided by the RCM/OCT device. In addition, will determine the quality of life before and after treatment by having the participant fill out questionnaires.

注册库
clinicaltrials.gov
开始日期
2022年3月3日
结束日期
2027年3月1日
最后更新
12天前
研究类型
Interventional
研究设计
Single Group
性别
All

研究者

入排标准

入选标准

  • Biopsy proven basal cell carcinoma
  • °Up to 3 tumors per patient can be treated per protocol synchronously or metachronously
  • Clinical stage T1 or T2 by Union International to Control Cancer 8th edition system
  • ≤40 mm in maximum dimension
  • no deep invasion (beyond subcutaneous fat or \>6 mm from granular later of dermis to deepest point of carcinoma)
  • no perineural invasion of nerves ≥0.1 mm diameter or deeper than dermis
  • no intraneural invasion
  • no bone erosion, invasion or foraminal transgression NOTE: For the purposes of protocol inclusion, if any of the features mentioned above is not included in the pathology report they will considered absent.
  • ≥18 years old
  • Amenable to RCM/OCT and radiation therapy in opinion of investigator

排除标准

  • Medical contraindication to radiation therapy in the opinion of the investigator
  • Prior cancer radiotherapy which precludes the ability to safely deliver radiation therapy in the opinion of the investigator
  • High likelihood of protocol non-compliance in the opinion of the investigator °Patients who demonstrate unwillingness to undergo protocol-defined treatment or follow-up procedures will be ineligible to participate

研究组 & 干预措施

Reflectance ConfocaL Microscopy And Optical Coherence Tomography Guided RadIation Therapy

If eligible, patients will undergo pretreatment RCM/OCT imaging, followed by RT. Six weeks after the completion of RT, patients will undergo post-treatment assessment with RCM/OCT and biopsy. If residual carcinoma is detected on the biopsy, surgical excision of the BCC will be performed. If no residual carcinoma is detected on the biopsy, the patient will be monitored for clinical evidence of recurrence for up to 3 years.

干预措施: Reflectance ConfocaL Microscopy And Optical Coherence Tomography Guided

Reflectance ConfocaL Microscopy And Optical Coherence Tomography Guided RadIation Therapy

If eligible, patients will undergo pretreatment RCM/OCT imaging, followed by RT. Six weeks after the completion of RT, patients will undergo post-treatment assessment with RCM/OCT and biopsy. If residual carcinoma is detected on the biopsy, surgical excision of the BCC will be performed. If no residual carcinoma is detected on the biopsy, the patient will be monitored for clinical evidence of recurrence for up to 3 years.

干预措施: Radiation Therapy

结局指标

主要结局

histologic tumor response rate

时间窗: 6 weeks

The presence of residual carcinoma on a biopsy or surgical excision specimen will be primary determinant for the primary endpoint outcome.

次要结局

  • frequency and severity of adverse events(up to 12 weeks)

研究点 (14)

Loading locations...

相似试验